What moved the OSX.AX stock on 16 Jan 2026?

OSX.AX stock rose 50.00% on heavy retail trading and coverage of a regional distribution agreement. Volume was **104,517,211**, far above the average of **1,844,304**, creating a momentum-driven spike.

What are the main financial risks for Osteopore (OSX.AX)?

Key risks are negative EPS (**-0.04**), tiny market cap (**A$1.98m**), thin liquidity and execution risk on commercial deals. Regulatory hurdles and capital needs could also pressure the share price.

What is Meyka AI's outlook and forecast for OSX.AX stock?

Meyka AI's forecast model projects **A$0.08** in the near term versus current **A$0.012**, implying **566.67%** upside. Forecasts are projections and not guarantees; monitor revenue confirmation and earnings.

Is OSX.AX a buy after the spike?

After the spike, the stock shows overbought technicals and high volatility. Meyka AI gives a Grade **B** (score **67.24**) with a HOLD suggestion. Investors should wait for confirmed revenue and stability before adding exposure.

AU Stocks

OSX.AX Osteopore Limited ASX +50.00% on heavy volume 16 Jan 2026: liquidity test

ByHuzaifa Zahoor January 16, 2026

OSX.AX stock led ASX activity on 16 Jan 2026 after Osteopore Limited (OSX.AX) closed at A$0.012, up 50.00% on a volume surge of 104,517,211 shares. The market is closed for the session and the move made OSX.AX one of the most traded small-caps by volume. Traders flagged a distribution agreement reported in regional news and an extreme short-term technical setup that coincided with the spike. We outline what moved the price, the balance sheet signals, and what to watch next for liquidity and valuation.